Aktie A1W1KK CYTOKINETICS, INCORPORATED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Cytokinetics, Incorporated

Aktien

A1W1KK

US23282W6057

CYTK

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 17.05.2024 		% 5 Tage % 1. Jan.
59,53 USD -0,65 % Intraday Chart für Cytokinetics, Incorporated -4,14 % -28,70 %
17.05. Cytokinetics, Incorporated gibt den Rücktritt von Sandford D. Smith als Verwaltungsrat bekannt CI
15.05. Transcript : Cytokinetics, Incorporated - Shareholder/Analyst Call

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
Cytokinetics Q1 Net Loss Narrows, Revenue Declines
Cytokinetics: Q1 Earnings Snapshot
Earnings Flash (CYTK) CYTOKINETICS INCORPORATED Posts Q1 Revenue $835,000, vs. Street Est of $0.9M
Cytokinetics Reports First Quarter 2024 Financial Results
Cytokinetics, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586
Cytokinetics, Incorporated Announces Topline Data from Phase 1 Clinical Study of Ck-4021586
Cytokinetics, Incorporated Announces CEDAR-HCM Is Open to Enrollment
Cytokinetics Insider Sold Shares Worth $1,012,265, According to a Recent SEC Filing
Cytokinetics to Hold Annual Meeting of Stockholders
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics Appoints Sung Lee as CFO
Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A1W1KK Aktie
  4. Nachrichten Cytokinetics, Incorporated
  5. Andere Sprachen